Home
overview

SMi is delighted to announce the 12th annual ADMET conference returning to London on the 12th - 13th June 2017, featuring a half day post-conference workshop on the 14th June!

 

ADMET technologies determine properties of a drug candidate in the preclinical stage of drug discovery, and poor ADMET properties are a major cause for a candidate to fail in drug development. ADME-Toxicology has allowed pharmaceutical manufacturing companies to minimize drug discovery time, complications and to reduce costs. The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties is to increase the success rate of compounds reaching the development stage.

 

*Source: http://bit.ly/2hMJcgU

 

Join our expert speaker panel at the 12th annual ADMET conference for yet another successful run! Presenting new developments, case studies and challenges in the areas of DMPK, PBPK, PKPD, in vivo / in vitro / in silico, transporters, hazard and safety assessment, ADMET modeling, and many more.

 

Previous attendee testimonials:

"Very focused conference with most recent and relevant contributions"

"Focused and highly relevant"

"Content of conference very good"

The 12th annual ADMET conference will cover new developments in various areas of the ADMET sector, such as DMPK, PBPK, PKPD, in vivo / in vitro / in silico, hazard and safety assessment, ADMET modeling, etc.

 

Join us this year in June to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

  • ADME/PK Optimisation for Drug Design and Discovery
  • Drug Screening Technology
  • In Vitro to Human In Vivo Translation
  • Physiologically Based PK Modeling
  • DMPK, PBPK, PKPD
  • Pre-/Clinical Toxicity
  • Accurate Human Dose Predictions
  • Transporters, Bioavailability, Formulation
  • Drug Delivery
  • Metabolism Studies
  • Drug-Drug Interactions
  • In vivo / in vitro / in silico
  • Hazard and Safety Assessment
  • Predictive Toxicology
  • Preclinical Pharmacology Testing

DMPK
Computational
Principle scientist
Drug metabolism
ADME Toxicologist
Research fellow
Computational scientist
PK/PD modeling
Toxicologist
Anatomy
Stem cell

Aptuit (Verona) S.r.l; Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim Pharma GmbH & Co. KG; Cancer Research Technology; Corning Life Sciences; Domainex; Galapagos NV; Genentech, Inc.; GSK; GW Pharmaceuticals plc; Imperial College; Imperial College London; Institute of Cancer Research; inVentiv Health Clinical; Johnson & Johnson; Johnson&Johnson Pharmaceutical R&D; LHASA Ltd; Novartis Institutes for BioMedical Research; Orion Corporation Orion Pharma; Oxagen Limited; Oxagen Ltd; Polyphor Ltd; Redx Pharma; Roche Pharmaceuticals; Sigma Aldrich; Sigma Aldrich Co Ltd; Sussex University; Takeda Cambridge Limited (TCB); The Research Network Ltd; U S Foodservice Baltimore Maryland; Ucb Pharma; University Of Basel; University Of Campinas; University Of East London; University Of Edinburgh; University Of Surrey; Vertex Pharmaceuticals; Xenotech; York Bioanalytical Solutions Limited;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Eric Blomme

Eric Blomme, Vice President Preclinical Safety, AbbVie
View Bio

9:10 Toxicology Strategies for Drug Discovery: Personal Thoughts

Eric Blomme

Eric Blomme, Vice President Preclinical Safety, AbbVie
View Bio

  • Issues with front-loading in vitro tox assays
  • What type and how many in vitro assays are necessary to identify problematic chemical matter
  • Addressing secondary pharmacology and chemical promiscuity
  • 9:45 Understanding CNS penetration – how far have we gotten?

    Andreas Reichel

    Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
    View Bio

  • Current concept and methods to assess brain pharmacokinetics
  • Unbound brain concentrations, Kpuu and PK/PD
  • Case studies to illustrate both the potential and limitations of the current concept
  • Open issues and questions

     

  • 10:20 Morning Coffee

    10:50 Understanding PK/PD during drug discovery

    Robert van Waterschoot

    Robert van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche
    View Bio

    11:25 Advanced In vitro Models for Studying Drug Absorption, Distribution, Metabolism and Elimination

    Kevin Jones

    Kevin Jones, Sales Manager, Corning Life Sciences

  • An overview of the current in vitro models for studying drug metabolism and transport: pros and cons
  • Introducing the advanced recombinant enzyme and transporter models developed using mammalian expression system
  • Overview of the product characterization and applications, including robust dynamic range, lot to lot consistency and validation with known clinically relevant substrates and inhibitors
  • 12:05 Networking Lunch

    13:15 Mechanistic modeling and simulations of oral drug absorption/food effect/PPI/PB IVIVC: opportunities and challenges

    Handan He

    Handan He, Section Head, Nonclinical PK/PD, Novartis
    View Bio

    13:50 PBPK modelling – Pragmatic application in drug development

    Jackie Bloomer

    Jackie Bloomer, Director, GSK
    View Bio

    14:25 Physiological Based Pharmacokinetic PBPK modeling – the road ahead

    Valeriu  Damian

    Valeriu Damian, Director System Modeling & Translational Biology, GSK
    View Bio

  • PBPK modelling has evolved in the last two decades from a few pioneering applications to regulatory acceptance. It may seem that PBPK has reached its peak potential – but has it?
  • EMA and the FDA have published draft PBPK guidance for industry insuring an increase use of PBPK modelling in regulatory submissions
  • Next few years will bring significant developments in PBPK science:  from data integration to pure prediction from structure, from oral and IV to dermal, inhaled, intramuscular, long acting, intraocular, from drug alone to drug and metabolites, from small molecules to large molecule constructs, from dissolution to formulation design, from ODE’s to partial differential equations (PDE’s)
  • We will explore directions in which PBPK is likely to develop providing examples and case studies
  • 15:00 Afternoon Tea

    15:30 Labelled free MS spectrometry for cellular drug concentrations and stability

    Elisabetta Chiarparin

    Elisabetta Chiarparin, Associate Director Oncology Medicinal Chemistry, AstraZeneca
    View Bio

    16:05 Novel in vitro and in vivo models for the study of drug transporters in discovery and development

    Eugene Chen

    Eugene Chen, Associate Scientist, Genentech, Inc.
    View Bio

    16:40 Allosteric TrkA inhibitors, from data mining to clinical candidate

    Kiyoyuki Omoto

    Kiyoyuki Omoto, Associate Research Fellow, Pfizer

    17:15 Chairman’s Closing Remarks and Close of Day One

    Eric Blomme

    Eric Blomme, Vice President Preclinical Safety, AbbVie
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Eric Blomme

    Eric Blomme, Vice President Preclinical Safety, AbbVie
    View Bio

    9:10 Physical Properties and their impact on ADMET parameters and profiles

    Rob Young

    Rob Young, Senior Scientific Investigator & GSK Associate Fellow, GSK
    View Bio

  • How physical properties influence ADMET parameters, compound progression and chances of success
  • Better insight from new standards in measurements and predictions of physical parameters
  • Improving the effectiveness of predictive methods
  • Influence of properties on toxicological outcomes
  •  

    9:45 Deciphering the mechanism of drug-induced liver injury (DILI) of Cinchophen

    Timothy Schulz-Utermoehl

    Timothy Schulz-Utermoehl, Director of DMPK, Sygnature Discovery
    View Bio

  • Introduction to cinchophen toxicity in patients
  • In vitro ADME properties of cinchophen
  • In vivo preclinical excretion profile of cinchophen
  • Mechanistic studies using modern techniques to understand cinchophen-induced liver injury
  • 10:20 Holistic cellular models using primary cells for predicting drug clearance and toxicity

    Berend Oosterhuis

    Berend Oosterhuis, Chief Operating Officer, Solvo Biotechnology
    View Bio

  • B-Clear® screen in sandwich cultured hepatocytes to understand liver accumulation and biliary clearance potential early in development
  • HepatoPac® for metabolic clearance of slowly metabolising compounds and predictive toxicity measurements
  • PTC as a tool to study mechanisms of active renal clearance and toxicity
  • 11:00 Morning Coffee

    11:30 Addressing the continuing challenges of making accurate human dose predictions

    Peter Littlewood

    Peter Littlewood, Director DMPK, Vertex Pharmaceuticals
    View Bio

  • Understanding the requirements
  • Understanding how to use in vitro data
  • Obtaining the right in vivo data in the right species
  • IVIVC
  • Dealing with non P450 clearance pathways
  • Incorporating errors and variability into predictions
  • 12:05 Estimation of human volume of distribution; methods, accuracy and impact in human dose prediction

    Carl Petersson

    Carl Petersson, Associate Director Drug Disposition, Merck KGaA
    View Bio

    12:40 Networking Lunch

    13:40 Assessment of therapeutic index: Moving beyond single point estimate

    Karelle Menochet

    Karelle Menochet, Principal Scientist, UCB
    View Bio

    14:15 Drug-Drug Interactions Involving Transporters – Theory and Practice

    Matthias Wittwer

    Matthias Wittwer, Laboratory Head DMPK, Bayer
    View Bio

  • Short background on the subject
  • Interesting examples from literature
  • Bayer case-examples
  • 14:50 Utility of endogenous probes for predicting transporter mediated drug-drug interactions

    Kunal Taskar

    Kunal Taskar, Senior Investigator & Associate Fellow, GSK
    View Bio

  • Endogenous transporter substrates
  • Review of assessments to identify appropriate endogenous markers for predicting  transporter activity/modulations
  • Relevance of transporter biomarkers in the clinic and application in the predictions of transporter mediated DDIs
  • 15:25 Afternoon Tea

    15:55 Impact of Drug-Excipient Interactions on Pharmacokinetics

    Ajit Narang

    Ajit Narang, Sr. Scientist, Genentech
    View Bio

  • Overview of Pharmacokinetic Impact of Drug-Excipient Interactions
  • Case Study: Oral drug absorption impact of drug-croscarmellose in a tablet
  • Case Study: Intravenous pharmacokinetics of drug-cyclodextrin interaction in solution
  • Discussion: Role of drug self-association on pharmacokinetics and influencing drug-excipient interactions
  • 16:30 Quantitative prediction of gut wall metabolism

    Sheila Annie Peters

    Sheila Annie Peters, Head, Translational Quantitative Pharmacology, Merck KGaA
    View Bio

  • In vivo, in situ and in vitro models for the prediction of gut metabolism
  • Challenges in the establishment of good preclinical models - species differences in the isoforms; regional abundances and activities of drug metabolizing enzymes; the interplay of enzyme-transporter proteins; and lack of knowledge on enzyme abundances and availability of empirical scaling factors
  • Focus on CYP3A
  • Current gaps in the mechanistic understanding and the prediction of gut metabolism and how they can be overcome in the future
  • 17:05 Chairman’s Closing Remarks and Close of Day Two

    Eric Blomme

    Eric Blomme, Vice President Preclinical Safety, AbbVie
    View Bio

    +

    FEATURED SPEAKERS

    Eric Blomme

    Eric Blomme

    Vice President Preclinical Safety, AbbVie
    Handan He

    Handan He

    Section Head, Nonclinical PK/PD, Novartis
    Timothy Schulz-Utermoehl

    Timothy Schulz-Utermoehl

    Director of DMPK, Sygnature Discovery
    Valeriu  Damian

    Valeriu Damian

    Director System Modeling & Translational Biology, GSK

    Ajit Narang

    Sr. Scientist, Genentech
    Ajit Narang

    Ajit Narang works for Genentech, Inc., in South San Francisco, CA as a Sr. Scientist involved in the pharmaceutics and biopharmaceutics of small molecules in preclinical and early clinical development of various dosage forms of small molecule drugs. He also serves as Adjunct Faculty at the Universities of Tennessee and Phoenix; Industrial Advisory Board member of Western Michigan University; a panel member of the Biopharmaceutics Technical Committee (BTC) of the Pharmaceutical Quality Research Institute (PQRI) in Arlington, VA; vice-Chair of the Formulation Design and Delivery (FDD) section of the American Association of Pharmaceutical Scientists (AAPS), and committee member of a Master’s Student at Campbell University, North Carolina.

    Ajit earned his Ph.D. from the University of Tennessee in Memphis, Masters in Pharmaceutics from the Banaras Hindu University in India, and Bachelors in Pharmaceutical Sciences from the University of Delhi in India.

    He has over 15 years of drug produt development experience working for Bristol-Myers Squibb, Co. (BMS) in New Jersey, Wockhardt Pharmaceuticals (ex-Morton Grove Pharmaceuticals) in Illinois, and Ranbaxy Research Labs in India in different capacities.

    Ajit has contributed to several preclinical, clinical, and commercialized drug products including NDAs, ANDAs, and 505B2s. He is credited with over 40 peer-reviewed articles; 2 books; 7 patent applications; 20 invited talks; and 60 presentations at various scientific meetings.

    His current research interests are translation from preclinical to clinical and commercial drug product design; incorporation of QbD elements in drug product development; and mechanistic understanding of the role of material properties on product performance.

    Andreas Reichel

    VP, Head Research Pharmacokinetics, Bayer
    Andreas Reichel

    Andreas is Vice President and Head of Research Pharmacokinetics at Bayer Pharma Drug Discovery. His department has two sites (Berlin and Wuppertal) and is responsible for the DMPK and bioanalytics support of drug discovery projects of all therapeutic areas of the portfolio including cardiology, oncology, hematology, gynaecological therapy, and ophthalmology.
    Andreas received his PhD in Cell Biology from the University of Leipzig in 1994 studying the regulation of nutrient transport processes at the blood-brain barrier (BBB) in vivo under the supervision of Prof. Armin Ermisch.
    Between 1994 and 1997 he was working in the laboratories of Profs. Joan Abbott and David Begley, King’s College London, where he became interested in in vitro models of the BBB. Funded by several pharmaceutical companies he started working on approaches to assess and predict the CNS penetration of drugs. In 1997, Andreas joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his area of expertise to intestinal and hepatic transport processes and their relevance to drug absorption, drug disposition and drug-induced liver toxicity. In 2000, Andreas joined Schering AG in Berlin where he helped setting up and soon became to lead the department of Research Pharmacokinetics (RPK) with responsibility for in vitro ADME assays, in vivo PK studies as well as all PK and PK/PD modelling activities to predict the PK and the therapeutic dose in human. After the merger with Bayer in 2006, both RPK departments were combined under his leadership supporting all drug discovery projects starting from lead discovery, through to lead optimisation and candidate selection and profiling, and beyond for both small molecules and biologics.

    Berend Oosterhuis

    Chief Operating Officer, Solvo Biotechnology
    Berend Oosterhuis

    Mr. Oosterhuis holds a Master’s Degree in Biotechnology from the Wageningen University and Research Centre in The Netherlands. After graduating, Mr. Oosterhuis began his career at SOLVO in 2005 as a scientist in the Research and Development Laboratory, where he worked on the interaction of ABC transporters with environmental toxicants and nutraceutical compounds. From 2008 to 2009 he was head of SOLVO’s Contract Research Laboratory. From 2010 to 2015 Mr. Oosterhuis served as Director/VP of Business Development. During that time he set up SOLVO’s sales teams in the US, Europe and Asia. He was also responsible for the publication of SOLVO’s Transporter Book and the organization of SOLVO’s Transporter Conferences. In 2016 he was promoted to COO.

    Carl Petersson

    Associate Director Drug Disposition, Merck KGaA
    Carl Petersson

    Carl Petersson is pharmacist by training and obtained his Ph.D in organic chemistry at the Swedish University of Agricultural Sciences. After post doctorial training at the University of Alberta, Canada, he began his industrial carrier in 1998 at Astra (later AstraZeneca) and remained there until 2012 having roles as associate director and principal scientist in the departments of development and discovery DMPK, toxicology and medicinal chemistry. Since 2012 he is an employee of Merck at the department of discovery DMPK focusing on early human dose predictions and optimization of pharmacokinetic properties.

    Elisabetta Chiarparin

    Associate Director Oncology Medicinal Chemistry, AstraZeneca
    Elisabetta Chiarparin

    Dr. Chiarparin is Head of Oncology Analytical and Structural Chemistry, associate director in Oncology Chemistry, AstraZeneca, Cambridge UK.
    Dr. Chiarparin has more than 15 years of experience in drug discovery and pharmaceutical research developed at Aventis Pharma (now Sanofi), GSK and Astex Pharmaceuticals and in AstraZeneca in the areas of biophysics, structural biology, structural and physical chemistry. Dr Chiarparin received a master degree in X-ray crystallography and a Ph.D. in Nuclear Magnetic Resonance (NMR) methodology under the supervision of Prof. Geoffrey Bodenhausen. Dr. Chiarparin is a member of the External Advisory Board Scientific of IDPbyNMR (Intrinsically disordered Protein by NMR) and of SMASH and Phys Chem Forum Scientific Organizing Committees.

    Eric Blomme

    Vice President Preclinical Safety, AbbVie
    Eric Blomme

    Eric joined Abbott/AbbVie in 2003 as a Project Leader in Discovery Advanced Technologies. He has held several positions at AbbVie, including Director, Investigative Toxicology and Pathology and Director, Integrated Pharmacology. Eric is currently Vice President, Preclinical Safety. Prior to joining AbbVie, he worked at Pharmacia and Searle.

    Eric attended the University of Lyon, McGill University, Cornell University and The Ohio State University and received his Doctor in Veterinary Medicine, PhD, and Pathology Certification. He is President of the Great Lake Chapter of the American Society of Pharmacology and Experimental Therapeutics. He has published over 70 peer-reviewed manuscripts, multiple editorials, several book chapters, and a book.

    Eugene Chen

    Associate Scientist, Genentech, Inc.
    Eugene Chen

    Dr. Eugene Chen is currently an Associate Scientist in the Drug Metabolism and Pharmacokinetics department at Genentech. He is responsible for supporting project teams from discovery to late stage clinical development through addressing permeability and transporter related questions. He completed his Ph.D. in Pharmaceutical Sciences and Pharmacogenomics at the University of California, San Francisco under the guidance of Dr. Kathleen Giacomini, investigating the endogenous function of organic cation transporters and their role in drug disposition and DDIs. His research interests are focused on understanding the contribution of transporters to the ADME and safety properties of drugs, by developing novel transporter assays and models.

    Handan He

    Section Head, Nonclinical PK/PD, Novartis
    Handan He

    Handan He, Ph.D. is currently Head of Computational and Biopharmaceutics Section at Novartis Pharmaceutical Corporation. Dr He is a recipient of the 2009 Outstanding 50 Asian Americans in Business Award. She received the highest Novartis Global VIVA Award (Vision, Innovation, Value, Achievement Award), which recognizes her as a life-long Leading Scientist. Dr He has 25 years industry experience and filed >30 INDs/NDAs, supporting all disease areas. Dr He has served as an invited speaker at national and international pharmaceutical and pharmacokinetic conferences including American Association of Pharmaceutical Scientists (AAPS), Society for Whole-body Autoradiography (SWBA), IBC life Science, Drug Information Association (DIA), Pharmaceutical Research and Manufacturers of America (PhRMA), World Pharma Congress (WPC) and OMICS International, The Laboratory Robotics Interest Group (LRIG), HT-ADME Boston Society, Applied Pharmaceutical Analysis and World Congress on Pharmaceutics and Novel Drug Delivery Systems. She has published more than 50 scientific papers and over 50 abstracts. She served as the elected President of Sino-American Pharmaceutical Professionals Association (SAPA) between 2012 and 2013 and currently is the chair of Board of Directors. She received her Ph.D. in drug metabolism and pharmacokinetics at the University of Saskatchewan in Canada.

    Jackie Bloomer

    Director, GSK
    Jackie Bloomer

    Jackie Bloomer has 30 yrs experience in preclinical DMPK with expertise in enzyme methodologies, extrapolation of in vitro data and application of physiologically based pharmacokinetic (PBPK) models. She has implemented in vitro strategies and methodologies in both drug discovery and development environments to enable assessment of the risk of clinical drug-drug interactions. She has promoted the application of in vitro-in vivo extrapolation techniques and dynamic modelling approaches including PBPK modelling for quantitative clinical predictions. She is co-chair of the Drug Interaction Advisory Committee within GSK with the remit of advising project teams on clinical drug interaction issues.

    Karelle Menochet

    Principal Scientist, UCB
    Karelle Menochet

    Karelle Ménochet is currently a principal scientist in the DMPK Strategy group at UCB, Slough (UK), working as a DMPK representative and biomarker leader on NCE and NBE projects. Previously, she worked as a DMPK scientist at AstraZeneca and Huntingdon Life Sciences in the UK and Parke-Davis/Pfizer in Fresnes (France) covering multiple aspects of DMPK in drug discovery projects. She has a PhD in Pharmaceutical Sciences from the University of Manchester (UK), an MSc in Genetics, Cell and Molecular Biology from the University of Nancy-Brabois (France) and a BSc in Applied Biology from the University of Paris XII. Her main research interest focusses on the translation of the impact of active transport on human pharmacokinetics from data generated in pre-clinical systems.

    Kevin Jones

    Sales Manager, Corning Life Sciences
    Kevin Jones

    Kiyoyuki Omoto

    Associate Research Fellow, Pfizer
    Kiyoyuki Omoto

    Kunal Taskar

    Senior Investigator & Associate Fellow, GSK
    Kunal Taskar

    Kunal Taskar, Ph.D., is currently working as an Associate GSK Fellow at GlaxoSmithKline, U.K. in Mechanistic Safety and Disposition, IVIVT R&D department. He is the transporter expert at the GSK UK site and consults on drug transporter related project questions from early drug discovery to post-marketing drug development. His past experience includes working as a drug transporter expert in the DMPK Pharmaceutical Candidate Optimization department at Biocon Bristol-Myers Squibb Research and Development. Kunal completed his doctorate and postdoctoral research at Texas Tech University Health Sciences department, USA, in Quentin Smith’s lab with research focused on drug delivery to central nervous system and role of transporters in drug delivery across the blood-brain barrier (BBB).

    Kunal’s experience and research focus include: drug-drug interaction predictions and mechanistic understanding of the clinically occurring drug–drug interactions; transporter mediated drug delivery and intracellular drug concentrations, especially the role of uptake (OATPs, OATS, OCTs, MATEs, PEPTs, other SLCs) and efflux (P-gp, BCRP, MRPs, other ABCs) transporters in drug pharmacokinetics-pharmacodynamics and disease and toxicology; novel transporters and role in drug disposition (research on critical role of novel transporters at the BBB); improvising current transporter assays and models for drug transporter studies and clinical predictions; and use of endogenous probes for drug mediated transporter modulations.

    Kunal is a member of American Association of Pharmaceutical Scientists (AAPS) and the International Brain Barriers Society. Kunal is also a member of the Predictive Safety Testing Consortium Hepatox working group focused on bile salt export pump transporter. He received the 2014 AAPS Pharmaceutical Research Meritorious Manuscript Award for a manuscript that was published in the same journal in 2012. He served as chair of the AAPS Texas Tech University student chapter in 2011, and chaired the Gordon-Kenan Research Seminar on Barriers of the CNS in 2010.
     

    Matthias Wittwer

    Laboratory Head DMPK, Bayer
    Matthias Wittwer

    Studies in pharmacy at the universities of Bern and Basel, Switzerland. PhD thesis in pharmaceutical sciences at the university of Basel involving the buildup of pharmacokinetic assays and their use for the characterization of NCEs. Postdoc in the field of drug transporters in the laboratory of Kathleen Giacomini at the University of California, San Francisco (UCSF). From July 2013 to October 2016 laboratory head in the department of research pharmacokinetics at Bayer AG (early PK project support as well as candidate selection and characterization using cellular and animal models). Currently laboratory head in the department of non-clinical pharmacokinetics at Bayer AG (PK support for development projects with a special focus on protein binding, drug transporters and DDIs).

    Peter Littlewood

    Director DMPK, Vertex Pharmaceuticals
    Peter Littlewood

    Dr Peter Littlewood started working in engineering, then changed career to the pharmaceutical industry and studied Chemistry at the University of Leicester. He has worked in DMPK for over 20 years at Merck, AstraZeneca, Organon, Scherring Plough, and currently at Vertex Pharmaceuticals Incorporated.
    Dr Littlewood has been at Vertex as Head of DMPK for six years now, and has worked on many projects and different disease areas. He has also run the UK center of excellence for global human PK and dose predictions for Vertex Pharmaceuticals Incorporated.

    Rob Young

    Senior Scientific Investigator & GSK Associate Fellow, GSK
    Rob Young

    Rob Young joined Wellcome in 1990, after completing undergraduate and D.Phil studies at Oxford University and a Post Doc at The Ben May Institute, University of Chicago. His subsequent medicinal chemistry career has seen many changes, mergers and acquisitions, encompassing significant contributions to six development candidates ( antivirals (HIV/HBV/Herpes), iNOS and Factor Xa). Moved to early stage discovery (2006), with contributions across numerous H2L programmes. A long term interest in Physical Properties and partnership with Alan Hill has produced impactful contributions to the field, further developing expertise in predictive methods. Author/inventor on 80 publications/patents; visiting Professor, University of St Andrews.

    Robert van Waterschoot

    Head of Pharmacokinetics, Dynamics & Metabolism PDM Leaders, Roche
    Robert van Waterschoot

    Dr. Robert van Waterschoot is currently heading the global Pharmacokinetics, Dynamics & Metabolism (PDM) Leaders group for small molecules at the Roche Innovation Centers in Basel and New York.
    Prior to his career at Roche, he acquired experience in the DMPK departments of Merck (USA), Solvay Pharmaceuticals (the Netherlands) and Abbott/AbbVie (Germany).
    Dr. Van Waterschoot has an MSc degree in Molecular Toxicology from the VU University Amsterdam and a PhD degree in Pharmacokinetics & Drug Toxicity from the Dutch Cancer Institute in Amsterdam. He has more then 20 peer-reviewed publications in the field of DMPK.

    Sheila Annie Peters

    Head, Translational Quantitative Pharmacology, Merck KGaA
    Sheila Annie Peters

    Dr. Sheila Annie Peters heads the Translational Quantitative Pharmacology group at Merck Darmstadt. Her areas of expertise in DMPK include Physiologically-based pharmacokinetic (PBPK)-Phamacodynamics (PD) modeling, and PK/PD and drug-drug interactions. In her previous position at AstraZeneca, Mölndal, she developed a generic whole-body PBPK model in MATLAB® which she used to support several drug discovery and early development projects across different R&D sites with innovative approaches to identifying potential limitations to drug disposition. She led the development of a pulmonary PBPK model for inhaled drugs in collaboration with Pharmaceutical Development at AstraZeneca. The work won the 2013 IMED (Innovative Medicines) Science Award at AstraZeneca for the “Design and Development of LungSim Simulation tool for Inhalation PK Modelling”. She successfully implemented Model-based drug discovery (MBDDx) strategy in RIA IMed at AstraZeneca by engaging leaders across different functions (DMPK, Bioscience, Translational Science and Clinical Pharmacology). Apart from publishing several papers in high impact journals, she also has published a book on PBPK in 2012 and co-authored a White Paper on PBPK along with other experts in industry.

    Timothy Schulz-Utermoehl

    Director of DMPK, Sygnature Discovery
    Timothy Schulz-Utermoehl

    Dr Schulz-Utermoehl has over 18 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He was a co-founder and director at Polleo Pharma, has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK & Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and Director of Belfry Therapeutics.

    Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.

    Valeriu Damian

    Director System Modeling & Translational Biology, GSK
    Valeriu  Damian

    Valeriu Damian is leading the Systems Modeling and Translational Biology group in GlaxoSmithKline. The group is responsible for providing translational modeling support for all therapeutic areas in GSK. This includes Physiological Based PK (PBPK), PK/PD, Quantitative Systems Pharmacology and Toxicology (QSP/T) modeling for all modalities and delivery routes.
    Valeriu holds a PhD in computer science from University of Iowa and a computer engineering diploma from Politehnica University of Bucharest in Romania. His carrier in GSK started in 1998 as a senior scientist in the Bioinformatics department initially responsible for the mathematical analysis and modeling of gene expression and proteomics data. After holding several positions in R&D-IT in the Scientific Computing and Mathematical Modeling group Valeriu joined the Platform Technology and Science organization in 2007 in the Biophysical Sensor and Nanomaterials group and later in the Open Innovation group before setting up and leading a translational modeling group initially in DMPK since 2011 and since 2015 in the newly formed Computational Modeling Sciences department.
    Valeriu focus has been on integrating diverse scientific ideas from multiple disciplines – mathematics, informatics, chemistry, physics, biology and engineering – into mechanistically based models and demonstrated their capability to interpret available data, to enhance understanding, to suggest testable hypotheses, to push the scientific boundaries and ultimately to bring better, faster and more affordable medication to the patients.

    Sponsors and Exhibitors

    Official Publication

    Supporters

    Workshops

    Drug Transporters Tool Kit
    Workshop

    Drug Transporters Tool Kit

    Holiday Inn Kensington Forum
    14th June 2017
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    ADMET 2017 PRELIMINARY ATTENDEE LIST

    Download

    An Interview with Handan He, Director, Section Head, Novartis

    Download

    Interview with Carl Petersson, Associate Director Drug Disposition, Merck KGaA

    Download

    Sponsors and Exhibitors


    Corning

    Sponsors and Exhibitors
    http://www.corning.com/lifesciences/

    Corning Incorporated offers integrated solutions to support life sciences and accelerate drug discovery and development with reagents and Contract Research Services for in vitro analysis of xenobiotic metabolism and drug transport. Products include Corning® Gentest™ Hepatocytes, Tissue Fractions, various transporter models, Corning Supersomes™ Enzymes, and Corning Gentest Contract Research Services


    SOLVO Biotechnology

    Sponsors and Exhibitors
    http://www.solvobiotech.com/

    SOLVO Biotechnology is the leading provider of transporter assays Worldwide, since 1999. With over 100 solutions, we support your in-house or outsourced projects with high quality products or services, including FDA-, EMA, PMDA-ready reports. Please visit www.solvobiotech.com!

    Media Partners


    International Pharmaceutical Industry

    Official Publication
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    International Journal of Behavioural and Healthcare Research

    Official Publication
    http://www.inderscience.com/ijbhr

    IJBHR addresses a broad range of original experimental and theoretical papers that deal with behavioural and healthcare concerns. It welcomes high-quality papers from scientists in academic and non-academic organisations as well as business and government worldwide. IJBHR is sponsored by the Business and Economics Society International and the Frontiers in Immunology Research Network.


    International Journal of Cognitive Biometrics

    Official Publication
    http://www.inderscience.com/ijcb

    Cognitive biometrics acquires information from users through collection of one or more biosignals. This relies on the presentation of one or more external or imagined stimuli. The subsequent response(s) are acquired and used for verification and authentication. IJCB addresses all aspects of cognitive biometrics, which aims to extract a unique signature from the user based on the cognitive, affective and conative state of the individual, either alone or more typically in various multi-modal combinations involving conventional and soft biometrics.


    International Journal of Computational Biology and Drug Design

    Official Publication
    http://www.inderscience.com/ijcbdd

    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.


    International Journal of Medical Engineering and Informatics

    Official Publication
    http://www.inderscience.com/ijmei

    IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.


    Int. J. of Immunological Studies

    Official Publication
    http://www.inderscience.com/ijis

    IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.

    Media Partners


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    RareBase

    Supporters
    http://www.rarebase.co.uk

    The RareBase Networking Portal links people and companies throughout the world with an interest in rare and paediatric diseases.


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    BioPharm Insight

    Supporters
    http://www.biopharminsight.com

    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    AntibodyChain

    Supporters
    http://www.antibodychain.com

    The complete and transparent marketplace for your research antibodies, kits, proteins and small molecules. The sophisticated search engine, with more than 800.000 products, transparency in suppliers, easy comparison, the one stop shop for your research antibodies in combination with interesting news and events plus a CMO exchange makes us a full service partner for you.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Bioscreening

    Supporters
    http://www.bioscreening.com



    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    CLocate

    Supporters
    http://www.clocate.com

    Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    European Biopharmaceutical Review

    Supporters
    http://www.samedanltd.com/magazine/12

    European Biopharmaceutical Review (EBR) is a magazine dedicated to the biopharmaceutical and biotech industries. Each quarterly edition features articles from key opinion leaders on research, drug discovery and development, biomanufacturing, outsourcing and more on the science and business of the sectors. EBR also features insightful interviews, reviews and event information to form a strong B2B platform. Read EBR in print, online, or via the Samedan app.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Samedan

    Supporters
    http://www.samedanltd.com/magazine/13.

    International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


    Pharmaceutical-Tech

    Supporters
    http://www.pharmaceutical-tech.com

    In the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers. Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.